Stay updated on Pembrolizumab in Untreated B-Cell NHL Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Untreated B-Cell NHL Clinical Trial page.

Latest updates to the Pembrolizumab in Untreated B-Cell NHL Clinical Trial page
- Check4 days agoChange DetectedA minor template/version update was applied: Revision v3.3.4 replacing v3.3.3, with no changes to study content or page functionality; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check12 days agoNo Change Detected
- Check19 days agoNo Change Detected
- Check26 days agoChange DetectedA dedicated Locations section was added, listing Washington as a study location. The HHS Vulnerability Disclosure link and the standalone Washington Locations entry were removed, and the revision updated to v3.3.3.SummaryDifference0.2%

- Check48 days agoChange DetectedPage revision updated from v3.3.1 to v3.3.2. No substantive study information appears to change.SummaryDifference0.1%

- Check55 days agoChange DetectedFooter updated to Revision: v3.3.1, replacing the previous Revision: v3.2.0. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check62 days agoChange DetectedTimestamp updates were added to the study record, including Last Update Posted (Estimated) and new date entries such as 2025-10-28, 2025-10, and 2025-11-12. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.7%

- Check76 days agoChange DetectedNo additions or deletions detected; the page content appears unchanged.SummaryDifference0.5%

Stay in the know with updates to Pembrolizumab in Untreated B-Cell NHL Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Untreated B-Cell NHL Clinical Trial page.